reSET® available by prescription for Substance Use Disorder
Pear's lead product, an FDA-cleared 12-week prescription-only therapeutic, is prescribed as an adjunct to standard outpatient treatment.
Newsroom
News and announcements
Updates on our products, pipeline, and the growing category of prescription digital therapeutics.
reSET-O™ advances toward FDA clearance for opioid use disorder
The program extends Pear's platform to OUD, designed to work alongside medication-assisted treatment.
New programs in schizophrenia, PTSD, and anxiety
THRIVE™, reCALL™, and reVIVE™ join a pipeline that also spans pain, major depressive disorder, and insomnia.
Building the category of prescription digital therapeutics
Pear continues to work with clinicians, payers, and regulators to establish standards for validated, prescribed software.
Media inquiries
Journalists and analysts can reach our communications team through the contact page.